- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00370760
Oral Colchicine Combined With Intravitreal Infusion of Dexamethasone, LMW Heparin and 5-FU for Management of Proliferative Vitreoretinopathy (PVR)
June 25, 2008 updated by: Shahid Beheshti University of Medical Sciences
To evaluate the efficacy of oral colchicine combined with intraoperative infusion of dexamethasone, low molecular weight heparin and 5-FU during vitrectomy for management of established proliferative vitreoretinopathy (PVR)
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Study Type
Interventional
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Hamid Ahmadieh, MD
- Phone Number: +98 21 22585952
- Email: hahmadieh@hotmail.com
Study Locations
-
-
-
Tehran, Iran, Islamic Republic of, 16666
- Recruiting
- Hamid Ahmadieh, MD
-
Contact:
- Hamid Ahmadieh, MD
- Phone Number: +98 21 22585952
- Email: hahmadieh@hotmail.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Cases with rhegmatogenous retinal detachment complicated by PVR grade C
Exclusion Criteria:
- History of pars plana vitrectomy for PVR grade C
- History of silicone oil injection
- History of ocular trauma
- Diabetic retinopathy
- Glaucoma
- Giant retinal tear
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: 2
|
|
Active Comparator: 1
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Retinal reattachment rate
|
Secondary Outcome Measures
Outcome Measure |
---|
visual acuity
|
PVR recurrence,
|
macular pucker,
|
reoperation,
|
ocular hypotony,
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2006
Study Registration Dates
First Submitted
August 30, 2006
First Submitted That Met QC Criteria
August 30, 2006
First Posted (Estimate)
September 1, 2006
Study Record Updates
Last Update Posted (Estimate)
June 26, 2008
Last Update Submitted That Met QC Criteria
June 25, 2008
Last Verified
June 1, 2008
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Eye Diseases
- Retinal Diseases
- Vitreoretinopathy, Proliferative
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Fibrinolytic Agents
- Fibrin Modulating Agents
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antiemetics
- Gastrointestinal Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Anticoagulants
- Gout Suppressants
- Dexamethasone
- Heparin
- Colchicine
- Heparin, Low-Molecular-Weight
- Tinzaparin
- Dalteparin
Other Study ID Numbers
- 8404 (Other Identifier: FCDGC)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Proliferative Vitreoretinopathy
-
Shahid Beheshti University of Medical SciencesUnknownProliferative VitreoretinopathyIran, Islamic Republic of
-
Shahid Beheshti University of Medical SciencesCompletedProliferative VitreoretinopathyIran, Islamic Republic of
-
Stanford UniversityWithdrawnProliferative VitreoretinopathyUnited States
-
Shahid Beheshti University of Medical SciencesUnknownProliferative VitreoretinopathyIran, Islamic Republic of
-
Centro Oftalmológico Dr CharlesCompletedProliferative VitreoretinopathyArgentina
-
National Eye Institute (NEI)CompletedRetinal Detachment | Proliferative Vitreoretinopathy
-
Wills EyeCompletedProliferative VitreoretinopathyUnited States
-
University of Health Sciences LahoreRecruitingProliferative VitreoretinopathyPakistan
-
Shanghai 10th People's HospitalUnknown
Clinical Trials on placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States